-
1
-
-
71649099089
-
Crossreactive immunologic material status affects treatment outcomes in Pompe disease infants
-
Kishnani PS, Goldenberg PC, Dearmey SL, et al. Crossreactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33.
-
(2010)
Mol Genet Metab
, vol.99
, pp. 26-33
-
-
Kishnani, P.S.1
Goldenberg, P.C.2
Dearmey, S.L.3
-
2
-
-
71949101824
-
Pompe disease in infants: Improving the prognosis by newborn screening and early treatment
-
Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-e1125.
-
(2009)
Pediatrics
, vol.124
, pp. e1116-e1125
-
-
Chien, Y.H.1
Lee, N.C.2
Thurberg, B.L.3
-
3
-
-
78649323564
-
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa
-
De Vries JM, Van Der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010;101:338-345.
-
(2010)
Mol Genet Metab
, vol.101
, pp. 338-345
-
-
De Vries, J.M.1
Van Der-Beek, N.A.2
Kroos, M.A.3
-
4
-
-
84862827574
-
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibodysecreting plasma cells
-
Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibodysecreting plasma cells. Mol Genet Metab 2012;105:677-680.
-
(2012)
Mol Genet Metab
, vol.105
, pp. 677-680
-
-
Banugaria, S.G.1
Patel, T.T.2
MacKey, J.3
-
5
-
-
0035746540
-
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial
-
Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
-
(2001)
Genet Med
, vol.3
, pp. 132-138
-
-
Amalfitano, A.1
Bengur, A.R.2
Morse, R.P.3
-
6
-
-
84881145296
-
Immune modulation therapy in a CRIM-positive and IgG antibodypositive infant with Pompe disease treated with alglucosidase alfa: A case report
-
Markic J, Polic B, Kuzmanic-Samija R, et al. Immune modulation therapy in a CRIM-positive and IgG antibodypositive infant with Pompe disease treated with alglucosidase alfa: a case report. JIMD Rep 2012;2:11-15.
-
(2012)
JIMD Rep
, vol.2
, pp. 11-15
-
-
Markic, J.1
Polic, B.2
Kuzmanic-Samija, R.3
-
7
-
-
84897024760
-
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: A 3-year follow-up study
-
Markic J, Polic B, Stricevic L, et al. Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. Wien Klin Wochenschr 2014;126:133-137.
-
(2014)
Wien Klin Wochenschr
, vol.126
, pp. 133-137
-
-
Markic, J.1
Polic, B.2
Stricevic, L.3
-
8
-
-
84855542158
-
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
-
Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012;14:135-142.
-
(2012)
Genet Med
, vol.14
, pp. 135-142
-
-
Messinger, Y.H.1
Mendelsohn, N.J.2
Rhead, W.3
-
9
-
-
84879340927
-
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: A step towards improving the efficacy of ERT
-
Banugaria SG, Prater SN, Patel TT, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PLoS One 2013;8:e67052.
-
(2013)
PLoS One
, vol.8
, pp. e67052
-
-
Banugaria, S.G.1
Prater, S.N.2
Patel, T.T.3
-
10
-
-
34548613865
-
Role of autophagy in the pathogenesis of Pompe disease
-
Raben N, Roberts A, and Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007;26:45-48.
-
(2007)
Acta Myol
, vol.26
, pp. 45-48
-
-
Raben, N.1
Roberts, A.2
Plotz, P.H.3
-
11
-
-
78649288882
-
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease
-
Raben N, Schreiner C, Baum R, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease. Autophagy 2010;6:1078-1089.
-
(2010)
Autophagy
, vol.6
, pp. 1078-1089
-
-
Raben, N.1
Schreiner, C.2
Baum, R.3
-
12
-
-
84877601173
-
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
-
Spampanato C, Feeney E, Li L, et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med 2013;5:691-706.
-
(2013)
EMBO Mol Med
, vol.5
, pp. 691-706
-
-
Spampanato, C.1
Feeney, E.2
Li, L.3
-
13
-
-
0142089744
-
Enzyme replacement therapy in the mouse model of Pompe disease
-
Raben N, Danon M, Gilbert AL, et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003;80:159-169.
-
(2003)
Mol Genet Metab
, vol.80
, pp. 159-169
-
-
Raben, N.1
Danon, M.2
Gilbert, A.L.3
-
14
-
-
27744533046
-
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II
-
Franco LM, Sun B, Yang X, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 2005;12:876-884.
-
(2005)
Mol Ther
, vol.12
, pp. 876-884
-
-
Franco, L.M.1
Sun, B.2
Yang, X.3
-
15
-
-
76349113832
-
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease
-
Sun B, Kulis MD, Young SP, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease. Mol Ther 2010;18:353-360.
-
(2010)
Mol Ther
, vol.18
, pp. 353-360
-
-
Sun, B.1
Kulis, M.D.2
Young, S.P.3
-
16
-
-
84861682930
-
Immunodominant liverspecific expression suppresses transgene-directed immune responses in murine Pompe disease
-
Zhang P, Sun B, Osada T, et al. Immunodominant liverspecific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum Gene Ther 2012; 23:460-472.
-
(2012)
Hum Gene Ther
, vol.23
, pp. 460-472
-
-
Zhang, P.1
Sun, B.2
Osada, T.3
-
17
-
-
34547498762
-
+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer
-
+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 2007;110:1132-1140.
-
(2007)
Blood
, vol.110
, pp. 1132-1140
-
-
Cao, O.1
Dobrzynski, E.2
Wang, L.3
-
18
-
-
80053377114
-
Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease
-
Banati M, Hosszu Z, Trauninger A, et al. Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease. Muscle Nerve 2011;44:720-726.
-
(2011)
Muscle Nerve
, vol.44
, pp. 720-726
-
-
Banati, M.1
Hosszu, Z.2
Trauninger, A.3
-
19
-
-
0022642908
-
Induction of tolerance by monoclonal antibody therapy
-
Benjamin RJ, and Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-451.
-
(1986)
Nature
, vol.320
, pp. 449-451
-
-
Benjamin, R.J.1
Waldmann, H.2
-
20
-
-
0024549385
-
Induction of classical transplantation tolerance in the adult
-
Qin SX, Cobbold S, Benjamin R, et al. Induction of classical transplantation tolerance in the adult. J Exp Med 1989;169:779-794.
-
(1989)
J Exp Med
, vol.169
, pp. 779-794
-
-
Qin, S.X.1
Cobbold, S.2
Benjamin, R.3
-
21
-
-
0027272545
-
Prevention of diabetes but not insulitis in NOD mice injected with antibody to CD4
-
Hayward AR, Shriber M, Cooke A, et al. Prevention of diabetes but not insulitis in NOD mice injected with antibody to CD4. J Autoimmun 1993;6:301-310.
-
(1993)
J Autoimmun
, vol.6
, pp. 301-310
-
-
Hayward, A.R.1
Shriber, M.2
Cooke, A.3
-
22
-
-
7244242322
-
Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: Influence on macrophage activation
-
Nissler K, Pohlers D, Huckel M, et al. Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation. Ann Rheum Dis 2004;63:1470-1477.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1470-1477
-
-
Nissler, K.1
Pohlers, D.2
Huckel, M.3
-
23
-
-
14844352743
-
+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: Antigen-specific reactivation in vivo is critical for bystander regulation
-
+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005;105:4871-4877.
-
(2005)
Blood
, vol.105
, pp. 4871-4877
-
-
Karim, M.1
Feng, G.2
Wood, K.J.3
-
24
-
-
84916603606
-
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
-
Sun B, Banugaria SG, Prater SN, et al. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab 2014;1:446-450.
-
(2014)
Mol Genet Metab
, vol.1
, pp. 446-450
-
-
Sun, B.1
Banugaria, S.G.2
Prater, S.N.3
-
25
-
-
84855445997
-
Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine
-
McIntosh JH, Cochrane M, Cobbold S, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther 2011;19:78-85.
-
(2011)
Gene Ther
, vol.19
, pp. 78-85
-
-
McIntosh, J.H.1
Cochrane, M.2
Cobbold, S.3
-
26
-
-
0346777307
-
Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
-
McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10:2112-2118.
-
(2003)
Gene Ther
, vol.10
, pp. 2112-2118
-
-
McCarty, D.M.1
Fu, H.2
Monahan, P.E.3
-
27
-
-
10944239670
-
Efficacy of an adenoassociated virus 8-pseudotyped vector in glycogen storage disease type II
-
Sun B, Zhang H, Franco LM, et al. Efficacy of an adenoassociated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005;11:57-65.
-
(2005)
Mol Ther
, vol.11
, pp. 57-65
-
-
Sun, B.1
Zhang, H.2
Franco, L.M.3
-
28
-
-
0037015049
-
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
-
Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-11859.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 11854-11859
-
-
Gao, G.P.1
Alvira, M.R.2
Wang, L.3
-
29
-
-
0033529902
-
Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase
-
Amalfitano A, Mcvie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A 1999;96:8861-8866.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 8861-8866
-
-
Amalfitano, A.1
McVie-Wylie, A.J.2
Hu, H.3
-
30
-
-
0036226791
-
Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction
-
Ding E, Hu H, Hodges BL, et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002;5:436-446.
-
(2002)
Mol Ther
, vol.5
, pp. 436-446
-
-
Ding, E.1
Hu, H.2
Hodges, B.L.3
-
31
-
-
0028027043
-
Mechanisms in CD4 antibody-mediated transplantation tolerance: Kinetics of induction, antigen dependency and role of regulatory T cells
-
Scully R, Qin S, Cobbold S, et al. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur J Immunol 1994;24:2383-2392.
-
(1994)
Eur J Immunol
, vol.24
, pp. 2383-2392
-
-
Scully, R.1
Qin, S.2
Cobbold, S.3
-
32
-
-
4644328028
-
Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody
-
Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol 2004;173: 4715-4723.
-
(2004)
J Immunol
, vol.173
, pp. 4715-4723
-
-
Winsor-Hines, D.1
Merrill, C.2
O'Mahony, M.3
-
33
-
-
78649508777
-
Antibody formation and mannose- 6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease
-
Sun B, Li S, Bird A, et al. Antibody formation and mannose- 6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease. J Gene Med 2010;12:881-891.
-
(2010)
J Gene Med
, vol.12
, pp. 881-891
-
-
Sun, B.1
Li, S.2
Bird, A.3
-
34
-
-
84864006285
-
The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease
-
Khanna R, Flanagan JJ, Feng J, et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One 2012;7:e40776.
-
(2012)
PLoS One
, vol.7
, pp. e40776
-
-
Khanna, R.1
Flanagan, J.J.2
Feng, J.3
-
35
-
-
19444362297
-
Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter
-
Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther 2005;11: 889-898.
-
(2005)
Mol Ther
, vol.11
, pp. 889-898
-
-
Sun, B.1
Zhang, H.2
Franco, L.M.3
-
36
-
-
0030795691
-
Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration
-
Halbert CL, Standaert TA, Aitken ML, et al. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997;71: 5932-5941.
-
(1997)
J Virol
, vol.71
, pp. 5932-5941
-
-
Halbert, C.L.1
Standaert, T.A.2
Aitken, M.L.3
-
37
-
-
17044394814
-
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV28-mediated liver-directed gene therapy
-
Wang LL, Calcedo R, Nichols TC, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV28-mediated liver-directed gene therapy. Blood 2005;105:3079-3086.
-
(2005)
Blood
, vol.105
, pp. 3079-3086
-
-
Wang, L.L.1
Calcedo, R.2
Nichols, T.C.3
-
38
-
-
84860155178
-
Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia
-
Demaster A, Luo X, Curtis S, et al. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. Hum Gene Ther 2012;23:407-418.
-
(2012)
Hum Gene Ther
, vol.23
, pp. 407-418
-
-
Demaster, A.1
Luo, X.2
Curtis, S.3
-
39
-
-
0036099319
-
Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors
-
Fraites TJ, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002;5:571-578.
-
(2002)
Mol Ther
, vol.5
, pp. 571-578
-
-
Fraites, T.J.1
Schleissing, M.R.2
Shanely, R.A.3
-
40
-
-
33847206112
-
Physiological correction of Pompe disease by systemic delivery of adenoassociated virus serotype 1 vectors
-
Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adenoassociated virus serotype 1 vectors. Mol Ther 2007;15: 501-507.
-
(2007)
Mol Ther
, vol.15
, pp. 501-507
-
-
Mah, C.1
Pacak, C.A.2
Cresawn, K.O.3
-
41
-
-
13844264229
-
Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alphaglucosidase in a model of glycogen storage disease type II
-
Cresawn KO, Fraites TJ, Wasserfall C, et al. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alphaglucosidase in a model of glycogen storage disease type II. Hum Gene Ther 2005;16:68-80.
-
(2005)
Hum Gene Ther
, vol.16
, pp. 68-80
-
-
Cresawn, K.O.1
Fraites, T.J.2
Wasserfall, C.3
-
42
-
-
35348926853
-
Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance
-
Sun B, Bird A, Young SP, et al. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007;81: 1042-1049.
-
(2007)
Am J Hum Genet
, vol.81
, pp. 1042-1049
-
-
Sun, B.1
Bird, A.2
Young, S.P.3
-
43
-
-
80051799963
-
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
-
Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011;13:729-736.
-
(2011)
Genet Med
, vol.13
, pp. 729-736
-
-
Banugaria, S.G.1
Prater, S.N.2
Ng, Y.K.3
-
44
-
-
80455174006
-
Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector
-
Luo X, Hall G, Li S, et al. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. Mol Ther 2011;19:1961-1970.
-
(2011)
Mol Ther
, vol.19
, pp. 1961-1970
-
-
Luo, X.1
Hall, G.2
Li, S.3
-
45
-
-
84908242541
-
Deficiency in MyD88 signaling results in decreased antibody responses to an adenoassociated virus vector in murine Pompe disease
-
Zhang P, Luo X, Bird A, et al. Deficiency in MyD88 signaling results in decreased antibody responses to an adenoassociated virus vector in murine Pompe disease. Biores Open Access 2012;1:109-114.
-
(2012)
Biores Open Access
, vol.1
, pp. 109-114
-
-
Zhang, P.1
Luo, X.2
Bird, A.3
-
46
-
-
46249131028
-
Ability of adenoassociated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice
-
Ziegler RJ, Bercury SD, Fidler J, et al. Ability of adenoassociated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 2008;19:609-621.
-
(2008)
Hum Gene Ther
, vol.19
, pp. 609-621
-
-
Ziegler, R.J.1
Bercury, S.D.2
Fidler, J.3
-
47
-
-
84921528269
-
Assessment of toxicity and biodistribution of recombinant AAV2/8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease
-
Wang G, Young S, Bali D, et al. Assessment of toxicity and biodistribution of recombinant AAV2/8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev 2014;1:14018.
-
(2014)
Mol Ther Methods Clin Dev
, vol.1
, pp. 14018
-
-
Wang, G.1
Young, S.2
Bali, D.3
-
48
-
-
48349114962
-
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy
-
Sun B, Young SP, Li P, et al. Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther 2008;16:1366-1371.
-
(2008)
Mol Ther
, vol.16
, pp. 1366-1371
-
-
Sun, B.1
Young, S.P.2
Li, P.3
-
49
-
-
34547514608
-
Muscle as a target for supplementary factor IX gene transfer
-
Hoffman BE, Dobrzynski E, Wang L, et al. Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 2007;18:603-613.
-
(2007)
Hum Gene Ther
, vol.18
, pp. 603-613
-
-
Hoffman, B.E.1
Dobrzynski, E.2
Wang, L.3
-
50
-
-
78650608742
-
FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
-
Nimmerjahn F, Lux A, Albert H, et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 2010;107:19396-19401.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 19396-19401
-
-
Nimmerjahn, F.1
Lux, A.2
Albert, H.3
-
51
-
-
7244236586
-
Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model
-
Xu F, Ding E, Liao SX, et al. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Gene Ther 2004; 11:1590-1598.
-
(2004)
Gene Ther
, vol.11
, pp. 1590-1598
-
-
Xu, F.1
Ding, E.2
Liao, S.X.3
-
52
-
-
33947196295
-
+ T cells are unable to eliminate AAVtransduced hepatocytes
-
+ T cells are unable to eliminate AAVtransduced hepatocytes. Mol Ther 2007;15:792-800.
-
(2007)
Mol Ther
, vol.15
, pp. 792-800
-
-
Li, H.1
Murphy, S.L.2
Giles-Davis, W.3
-
53
-
-
77954976233
-
Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: Implications for gene therapy using AAV sectors
-
Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV sectors. Hum Gene Ther 2010;21:704-771.
-
(2010)
Hum Gene Ther
, vol.21
, pp. 704-771
-
-
Boutin, S.1
Monteilhet, V.2
Veron, P.3
-
54
-
-
21244487991
-
Major role of local immune responses in antibody formation to factor IX in AAV gene transfer
-
Wang L, Cao O, Swalm B, et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005;12:1453-1464.
-
(2005)
Gene Ther
, vol.12
, pp. 1453-1464
-
-
Wang, L.1
Cao, O.2
Swalm, B.3
-
55
-
-
84863480768
-
Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B
-
Mingozzi F, Chen Y, Murphy SL, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther 2012;20:1410-1416.
-
(2012)
Mol Ther
, vol.20
, pp. 1410-1416
-
-
Mingozzi, F.1
Chen, Y.2
Murphy, S.L.3
-
56
-
-
84878746264
-
Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy
-
Louis Jeune V, Joergensen JA, Hajjar RJ, et al. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013;24:59-67.
-
(2013)
Hum Gene Ther Methods
, vol.24
, pp. 59-67
-
-
Louis Jeune, V.1
Joergensen, J.A.2
Hajjar, R.J.3
-
57
-
-
33745606715
-
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
-
Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006;108:107-115.
-
(2006)
Blood
, vol.108
, pp. 107-115
-
-
Jiang, H.1
Lillicrap, D.2
Patarroyo-White, S.3
-
58
-
-
33344466244
-
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
-
Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006;107:1810-1817.
-
(2006)
Blood
, vol.107
, pp. 1810-1817
-
-
Scallan, C.D.1
Jiang, H.2
Liu, T.3
-
59
-
-
80052496589
-
Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors
-
Wang L, Calcedo R, Bell P, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011;22: 1389-1401.
-
(2011)
Hum Gene Ther
, vol.22
, pp. 1389-1401
-
-
Wang, L.1
Calcedo, R.2
Bell, P.3
-
60
-
-
77957943865
-
Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia
-
Weinstein DA, Correia CE, Conlon T, et al. Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum Gene Ther 2010;21:903-910.
-
(2010)
Hum Gene Ther
, vol.21
, pp. 903-910
-
-
Weinstein, D.A.1
Correia, C.E.2
Conlon, T.3
-
61
-
-
0000995321
-
Glycogen storage disease type II: Acid α-glucosidase (acid maltase) deficiency
-
CR Scriver, AL Beaudet, WS Sly, and D Valle, eds. (McGraw-Hill, New York, NY)
-
Hirschhorn R, and Reuser AJJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: The Metabolic and Molecular Basis for Inherited Disease. CR Scriver, AL Beaudet, WS Sly, and D Valle, eds. (McGraw-Hill, New York, NY) 2001; pp. 3389-3419.
-
(2001)
The Metabolic and Molecular Basis for Inherited Disease
, pp. 3389-3419
-
-
Hirschhorn, R.1
Reuser, A.J.J.2
|